Relief Therapeutics Shareholders Approve Business Combination with NeuroX

Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Shareholders Approve Business Combination with NeuroX 14-Nov-2025 / 18:20 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Shareholders Approve Business Combination with NeuroX

• Shareholders approve all EGM proposals related to the combination with NeuroX
• Business combination expected to close in December 2025
• Relief to be renamed MindMaze Therapeutics Holding SA upon closing
• New board and executive committee members announced
• Companies to host joint press conference on November 25, 2025

GENEVA (Nov. 14, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced that shareholders approved by a large majority all resolutions submitted to its extraordinary general meeting (EGM) held earlier today in Geneva, Switzerland. The approvals authorize the business combination between Relief and NeuroX Group SA (NeuroX) to create a publicly listed, digital neurotherapeutics company combining NeuroX's brain health platform with Relief's specialty biopharmaceutical portfolio.

Shareholders approved an ordinary capital increase through the issuance of 140 million new ordinary shares, to be paid in by contribution in kind of NeuroX shares, together with amendments to the capital band and conditional capital. The EGM also approved renaming the Company to MindMaze Therapeutics Holding SA upon completion of the business combination and elected Walid Hanna, Olaf Blanke, Michael Stuenkel, and Martin Reiss to the board of directors, joining Gregory Van Beek upon closing. The remaining incumbent directors will step down at that time. Other approved resolutions included the election of the nomination and compensation committee and minor amendments to the Company's articles of association.